These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34543871)

  • 1. First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial.
    Morscher RJ; Brard C; Berlanga P; Marshall LV; André N; Rubino J; Aerts I; De Carli E; Corradini N; Nebchi S; Paoletti X; Mortimer P; Lacroix L; Pierron G; Schleiermacher G; Vassal G; Geoerger B
    Eur J Cancer; 2021 Nov; 157():268-277. PubMed ID: 34543871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study.
    Lapointe S; Mason W; MacNeil M; Harlos C; Tsang R; Sederias J; Luchman HA; Weiss S; Rossiter JP; Tu D; Seymour L; Smoragiewicz M
    Invest New Drugs; 2020 Aug; 38(4):1137-1144. PubMed ID: 31707687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial.
    Bautista F; Paoletti X; Rubino J; Brard C; Rezai K; Nebchi S; Andre N; Aerts I; De Carli E; van Eijkelenburg N; Thebaud E; Corradini N; Defachelles AS; Ducassou S; Morscher RJ; Vassal G; Geoerger B
    J Clin Oncol; 2021 Nov; 39(32):3546-3560. PubMed ID: 34347542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL.
    Eyre TA; Hildyard C; Hamblin A; Ali AS; Houlton A; Hopkins L; Royston D; Linton KM; Pettitt A; Rule S; Cwynarski K; Barrington SF; Warbey V; Wrench D; Barrans S; Hirst CS; Panchal A; Roudier MP; Harrington EA; Davies A; Collins GP
    Hematol Oncol; 2019 Oct; 37(4):352-359. PubMed ID: 31385336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.
    Basu B; Krebs MG; Sundar R; Wilson RH; Spicer J; Jones R; Brada M; Talbot DC; Steele N; Ingles Garces AH; Brugger W; Harrington EA; Evans J; Hall E; Tovey H; de Oliveira FM; Carreira S; Swales K; Ruddle R; Raynaud FI; Purchase B; Dawes JC; Parmar M; Turner AJ; Tunariu N; Banerjee S; de Bono JS; Banerji U
    Ann Oncol; 2018 Sep; 29(9):1918-1925. PubMed ID: 30016392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of orally administered
    MacDonald A; Scarfe G; Magirr D; Sarvotham T; Charlton J; Brugger W; Dean E
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):787-795. PubMed ID: 30758651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium.
    Pasqualini C; Rubino J; Brard C; Cassard L; André N; Rondof W; Scoazec JY; Marchais A; Nebchi S; Boselli L; Grivel J; Aerts I; Thebaud E; Paoletti X; Minard-Colin V; Vassal G; Geoerger B
    Eur J Cancer; 2021 Jun; 150():53-62. PubMed ID: 33892407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours.
    Rubie H; Geoerger B; Frappaz D; Schmitt A; Leblond P; Ndiaye A; Aerts I; Le Deley MC; Gentet JC; Paci A; Chastagner P; Dias N; Djafari L; Pasquet M; Chatelut E; Landman-Parker J; Corradini N; Vassal G
    Eur J Cancer; 2010 Oct; 46(15):2763-70. PubMed ID: 20558056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.
    Heudel P; Frenel JS; Dalban C; Bazan F; Joly F; Arnaud A; Abdeddaim C; Chevalier-Place A; Augereau P; Pautier P; Chakiba C; You B; Lancry-Lecomte L; Garin G; Marcel V; Diaz JJ; Treilleux I; Pérol D; Fabbro M; Ray-Coquard I
    JAMA Oncol; 2022 Jul; 8(7):1001-1009. PubMed ID: 35551299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition.
    Kim ST; Kim SY; Klempner SJ; Yoon J; Kim N; Ahn S; Bang H; Kim KM; Park W; Park SH; Park JO; Park YS; Lim HY; Lee SH; Park K; Kang WK; Lee J
    Ann Oncol; 2017 Mar; 28(3):547-554. PubMed ID: 28028034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual mTORC1/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth.
    Pi R; Yang Y; Hu X; Li H; Shi H; Liu Y; Wang X; Tong A; Lu T; Wei Y; Zhao X; Wei X
    Cancer Lett; 2021 Dec; 523():72-81. PubMed ID: 34560229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study.
    Le Teuff G; Castaneda-Heredia A; Dufour C; Jaspan T; Calmon R; Devos A; McHugh K; Leblond P; Frappaz D; Aerts I; Zwaan CM; Ducassou S; Chastagner P; Verschuur A; Corradini N; Casanova M; Rubie H; Riccardi R; Le Deley MC; Vassal G; Geoerger B;
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28032. PubMed ID: 31595663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial.
    Banerjee S; Giannone G; Clamp AR; Ennis DP; Glasspool RM; Herbertson R; Krell J; Riisnaes R; Mirza HB; Cheng Z; McDermott J; Green C; Kristeleit RS; George A; Gourley C; Lewsley LA; Rai D; Banerji U; Hinsley S; McNeish IA
    JAMA Oncol; 2023 May; 9(5):675-682. PubMed ID: 36928279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
    Wicki A; Brown N; Xyrafas A; Bize V; Hawle H; Berardi S; Cmiljanović N; Cmiljanović V; Stumm M; Dimitrijević S; Herrmann R; Prêtre V; Ritschard R; Tzankov A; Hess V; Childs A; Hierro C; Rodon J; Hess D; Joerger M; von Moos R; Sessa C; Kristeleit R
    Eur J Cancer; 2018 Jun; 96():6-16. PubMed ID: 29660598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study.
    Di Giannatale A; Dias-Gastellier N; Devos A; Mc Hugh K; Boubaker A; Courbon F; Verschuur A; Ducassoul S; Malekzadeh K; Casanova M; Amoroso L; Chastagner P; Zwaan CM; Munzer C; Aerts I; Landman-Parker J; Riccardi R; Le Deley MC; Geoerger B; Rubie H
    Eur J Cancer; 2014 Jan; 50(1):170-7. PubMed ID: 24021349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models.
    Hernández-Prat A; Rodriguez-Vida A; Juanpere-Rodero N; Arpi O; Menéndez S; Soria-Jiménez L; Martínez A; Iarchouk N; Rojo F; Albanell J; Brake R; Rovira A; Bellmunt J
    Mol Cancer Res; 2019 Sep; 17(9):1931-1944. PubMed ID: 31160383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel-sensitive and docetaxel-resistant castration-resistant prostate cancer cells.
    Li S; Sheng J; Liu Z; Fan Y; Zhang C; Lv T; Hu S; Jin J; Yu W; Song Y
    J Cell Mol Med; 2021 Mar; 25(5):2436-2449. PubMed ID: 33507584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors.
    Davis SL; Ionkina AA; Bagby SM; Orth JD; Gittleman B; Marcus JM; Lam ET; Corr BR; O'Bryant CL; Glode AE; Tan AC; Kim J; Tentler JJ; Capasso A; Lopez KL; Gustafson DL; Messersmith WA; Leong S; Eckhardt SG; Pitts TM; Diamond JR
    Clin Cancer Res; 2020 Sep; 26(17):4633-4642. PubMed ID: 32414750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.